Insurers drop obesity coverage

Health insurers pulled back sharply on obesity-drug coverage in 2026, leaving millions of Americans to pay cash, switch plans or stop treatment. (npr.org) Data reviewed by the health analytics firm MMIT found about 12 million people lost coverage for Eli Lilly’s Zepbound and roughly 12 million lost coverage for Novo Nordisk’s Wegovy between 2025 and 2026, NPR reported on April 22. The cuts hit some Affordable Care Act marketplace plans, employer coverage and other commercial insurance. (npr.org) These drugs are GLP-1 medicines, a class that helps people feel full longer and eat less; Zepbound is tirzepatide and Wegovy is semaglutide. Both are prescribed for chronic weight management, and Zepbound is also approved for adults with obesity and moderate-to-severe obstructive sleep apnea. (zepbound.lilly.com, wegovy.com) The coverage retreat came after employers and insurers spent 2024 and 2025 debating whether they could absorb the cost of drugs that can run hundreds of dollars a month even with manufacturer discount programs. Novo Nordisk says some eligible uninsured or uncovered patients can pay $349 a month for common Wegovy pen doses after introductory offers, while Eli Lilly advertises Zepbound self-pay pricing starting at $299 a month for some patients. (wegovy.com, zepbound.lilly.com) Patients who lose insurance coverage often do not simply stop trying to lose weight; NPR reported that some are changing to another branded drug, stretching doses or looking for compounded versions. That shift has continued even after federal regulators moved to wind down compounding tied to earlier shortages of Wegovy and Zepbound. (npr.org, npr.org) Medicare has not broadly covered drugs used only for weight loss, and a federal pilot meant to test wider coverage has run into delays. Reuters reported on April 22 that analysts did not expect the delay to hurt near-term demand much, in part because commercial coverage decisions are already pushing patients toward cash-pay and other channels. (usnews.com, usnews.com) UnitedHealth told investors this week that there are “challenges” around the Medicare pilot, adding to doubts about how many insurers will participate. Reuters reported on April 21 that the program, called Balance, had created uncertainty over whether health plans would sign up. (usnews.com) For patients, the immediate question is less about demand than access: whether their 2026 plan still covers the drug their doctor prescribed, and what the monthly bill becomes if it does not. The answer is increasingly determined by benefit design, not by whether Wegovy and Zepbound remain on the market. (npr.org, wegovy.com, zepbound.lilly.com)